

**Remarks/Arguments**

Reconsideration of this application, as amended, is respectfully requested.

**I. Status of the Claims**

After entry of these amendments, claims 1-17 are pending. Claim 19 is canceled. Claims 1-16 are amended at the request of the Examiner to recite "or a pharmaceutically acceptable salt thereof."

**II. Rejections Under 35 U.S.C. § 112, First Paragraph**

Method of treatment claim 19 stands rejected under 35 U.S.C. § 112, first paragraph, as lacking enablement. Claim 19 is canceled, thereby obviating this rejection. It is requested that the rejection be withdrawn.

**III. Rejections Under 35 U.S.C. § 112, Second Paragraph**

Claims 1, 13, 15 and 16 stand rejected under 35 U.S.C. § 112, second paragraph, as indefinite, on the grounds of the use of the term "and pharmaceutically acceptable salts thereof." At the request of the Examiner, claims 1, 13, 15 and 16 are amended to recite "or a pharmaceutically acceptable salt thereof.," thereby obviating this rejection. It is requested that the rejection be withdrawn.

**IV. Allowable Subject Matter**

The Examiner acknowledges at page 5 of the office action that claims 2-12, 14 and 17 are objected to as dependent upon a rejected base claim, but would be allowable if rewritten in independent form. In view of the action taken, it is believed that all claims 1-17 are now allowable.


**V. Conclusion**

In view of the action taken and arguments made, it is believed that all pending claims 1-17 are now in condition for allowance.

Favorable action is earnestly solicited.

Respectfully submitted,

By

  
\_\_\_\_\_  
John C. Todaro, Reg. No. 36,036  
Attorney for Applicants

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065  
Tel.: (732) 594-0125

Date: May 19, 2008